by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Elena Iemma | Jan 26, 2021 | Events, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
